

Human EGFR Monoclonal Antibody, Endotoxin 0.05 EU/mg

Catalog No.: YR0098

Basic Information

Molecular Weight

150 kDa

Endotoxin

<0.05EU/mg (<0.00005EU/µg)
Determined by LAL gel clotting assay

Sterility

0.2 µm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Nimotuzumab Biosimilar uses the same protein sequences as the therapeutic antibody nimotuzumab.Like cetuximab, nimotuzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division.It has a humanized human-mouse h-R3 heavy chain and a humanized human-mouse h-R3 κ-chain.Nimotuzumab binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor). This results in a blockade of ligand binding and receptor activation. Epidermal growth factor receptor (EGFR) is a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy.

Reported Applications

ELISA,neutralization,function al assays such as bioanalytical PK and ADA assays,and those assays for studying biological pathways

Immunogen Information

Clone

Nimotuzumab Biosimilar

Isotype

Human IgG1 kappa

Purification

Immunogen

Human EGFR

RecommendedIsotype Control(s)

In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

Recommended Dilution Buffer

1×PBS pH 7.4

Contact

www.abclonal.com

Product Information

Production

Purified from cell culture supernatant in an Protein A or G purification animal-free facility

Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)